Cargando…
1842. Fluoroquinolone Usage Reduction in the Outpatient Setting
BACKGROUND: Fluoroquinolones (FQ) are the leading class of antibiotics prescribed during adult ambulatory care visits, resulting in over 20 million outpatient prescriptions annually. Overuse of this class of antibiotics has contributed to increased antibiotic resistance and risk for Clostridioides d...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253047/ http://dx.doi.org/10.1093/ofid/ofy210.1498 |
_version_ | 1783373406562942976 |
---|---|
author | Mang, Norman Wei, Wenjing Ortwine, Jessica Prokesch, Bonnie |
author_facet | Mang, Norman Wei, Wenjing Ortwine, Jessica Prokesch, Bonnie |
author_sort | Mang, Norman |
collection | PubMed |
description | BACKGROUND: Fluoroquinolones (FQ) are the leading class of antibiotics prescribed during adult ambulatory care visits, resulting in over 20 million outpatient prescriptions annually. Overuse of this class of antibiotics has contributed to increased antibiotic resistance and risk for Clostridioides difficile infection. In 2016, the Food and Drug Administration (FDA) updated the Boxed Warnings advising against FQ use for patients with uncomplicated sinusitis, bronchitis, or cystitis as the risk for potential serious side effects outweighs the benefit. METHODS: The antimicrobial stewardship team at Parkland Health and Hospital System undertook a multi-interventional approach to decrease outpatient FQ usage (Figure 1). First, the FDA warning was added to all oral FQ orders in the electronic medical record and education regarding risk and appropriate use of FQ was given to providers in the primary care clinics and emergency department. Secondly, ciprofloxacin susceptibilities were suppressed by the laboratory when organisms were susceptible to third-generation cephalosporins. To assess the impact of these interventions, FQ utilization was compared across the same time period, each one year apart. Pre-education was assessed from November 2015 to February 2016, post-education from November 2016 to February 2017, and post-education plus susceptibility suppression from November 2017 to February 2018. RESULTS: Comparative utilization data by site was collected (Figure 2) with all sites demonstrating a decrease in FQ utilization and one site showing an 85% decrease. We observed an overall 19% decrease in outpatient FQ prescribing after education alone and 14% decrease after susceptibility suppression plus continuing education. Compared with pre-intervention baseline, there was a total 30% decrease in FQ utilization after both interventions were implemented, corresponding to approximately 150 fewer prescriptions per month (Figure 3). [Image: see text] [Image: see text] [Image: see text] CONCLUSION: Educational efforts alone proved effective in decreasing outpatient FQ usage. Additional improvement was observed when change was implemented at a system level via susceptibility suppression. Further decrease in FQ utilization is expected with ongoing education and additional system changes. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6253047 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62530472018-11-28 1842. Fluoroquinolone Usage Reduction in the Outpatient Setting Mang, Norman Wei, Wenjing Ortwine, Jessica Prokesch, Bonnie Open Forum Infect Dis Abstracts BACKGROUND: Fluoroquinolones (FQ) are the leading class of antibiotics prescribed during adult ambulatory care visits, resulting in over 20 million outpatient prescriptions annually. Overuse of this class of antibiotics has contributed to increased antibiotic resistance and risk for Clostridioides difficile infection. In 2016, the Food and Drug Administration (FDA) updated the Boxed Warnings advising against FQ use for patients with uncomplicated sinusitis, bronchitis, or cystitis as the risk for potential serious side effects outweighs the benefit. METHODS: The antimicrobial stewardship team at Parkland Health and Hospital System undertook a multi-interventional approach to decrease outpatient FQ usage (Figure 1). First, the FDA warning was added to all oral FQ orders in the electronic medical record and education regarding risk and appropriate use of FQ was given to providers in the primary care clinics and emergency department. Secondly, ciprofloxacin susceptibilities were suppressed by the laboratory when organisms were susceptible to third-generation cephalosporins. To assess the impact of these interventions, FQ utilization was compared across the same time period, each one year apart. Pre-education was assessed from November 2015 to February 2016, post-education from November 2016 to February 2017, and post-education plus susceptibility suppression from November 2017 to February 2018. RESULTS: Comparative utilization data by site was collected (Figure 2) with all sites demonstrating a decrease in FQ utilization and one site showing an 85% decrease. We observed an overall 19% decrease in outpatient FQ prescribing after education alone and 14% decrease after susceptibility suppression plus continuing education. Compared with pre-intervention baseline, there was a total 30% decrease in FQ utilization after both interventions were implemented, corresponding to approximately 150 fewer prescriptions per month (Figure 3). [Image: see text] [Image: see text] [Image: see text] CONCLUSION: Educational efforts alone proved effective in decreasing outpatient FQ usage. Additional improvement was observed when change was implemented at a system level via susceptibility suppression. Further decrease in FQ utilization is expected with ongoing education and additional system changes. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253047/ http://dx.doi.org/10.1093/ofid/ofy210.1498 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Mang, Norman Wei, Wenjing Ortwine, Jessica Prokesch, Bonnie 1842. Fluoroquinolone Usage Reduction in the Outpatient Setting |
title | 1842. Fluoroquinolone Usage Reduction in the Outpatient Setting |
title_full | 1842. Fluoroquinolone Usage Reduction in the Outpatient Setting |
title_fullStr | 1842. Fluoroquinolone Usage Reduction in the Outpatient Setting |
title_full_unstemmed | 1842. Fluoroquinolone Usage Reduction in the Outpatient Setting |
title_short | 1842. Fluoroquinolone Usage Reduction in the Outpatient Setting |
title_sort | 1842. fluoroquinolone usage reduction in the outpatient setting |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253047/ http://dx.doi.org/10.1093/ofid/ofy210.1498 |
work_keys_str_mv | AT mangnorman 1842fluoroquinoloneusagereductionintheoutpatientsetting AT weiwenjing 1842fluoroquinoloneusagereductionintheoutpatientsetting AT ortwinejessica 1842fluoroquinoloneusagereductionintheoutpatientsetting AT prokeschbonnie 1842fluoroquinoloneusagereductionintheoutpatientsetting |